Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 1:13:852215.
doi: 10.3389/fimmu.2022.852215. eCollection 2022.

Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives

Natalia Madetko  1 , Weronika Marzec  2 , Agata Kowalska  2 , Dominika Przewodowska  2 , Piotr Alster  1 , Dariusz Koziorowski  1
Affiliations
Review

Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives

Natalia Madetko et al. Front Immunol. .

Abstract

Anti-IgLON5 disease is a relatively new neurological entity with the first cases reported in 2014. So far, less than 70 articles on this topic have been published. Due to its unspecific symptomatology, diverse progression, novelty and ambiguous character, it remains a difficulty for both clinical practitioners and scientists. The aim of this review is to summarize the current knowledge concerning anti-IgLON5 disease; mechanisms underlying its cause, symptomatology, clinical progression, differential diagnosis and treatment, which could be helpful in clinical practice and future research.

Keywords: IgLON5 antibodies; IgLON5 disease; autoimmune disease; neurodegeneration; neuroinflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Possible heterogenous mechanism of anti-IgLON5 disease.
See this image and copyright information in PMC

References

    1. Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al. Clinical Manifestations of the Anti-IgLON5 Disease. Neurology (2017) 88(18):1736–43. doi: 10.1212/WNL.0000000000003887 - DOI - PMC - PubMed
    1. Vanaveski T, Singh K, Narvik J, Eskla KL, Visnapuu T, Heinla I, et al. Promoter-Specific Expression and Genomic Structure of IgLON Family Genes in Mouse. Front Neurosci (2017) 11:38. doi: 10.3389/fnins.2017.00038 - DOI - PMC - PubMed
    1. Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 Antibody: Neurological Accompaniments and Outcomes in 20 Patients. Neurol Neuroimmunol Neuroinflamm (2017) 4(5):e385. doi: 10.1212/NXI.0000000000000385 - DOI - PMC - PubMed
    1. Denton KM, Luff SE, Shweta A, Anderson WP. Differential Neural Control of Glomerular Ultrafiltration. Clin Exp Pharmacol Physiol (2004) 31(5-6):380–6. doi: 10.1111/j.1440-1681.2004.04002.x - DOI - PubMed
    1. da Silva C, da Silva G, Medeiros WLGJ, Gonçalves MVM. Anti-Iglon5 Syndrome: What We Know So Far? A Non-Systematic Review. J Neurol Neuromed (2020) 5(3):40–4. doi: 10.29245/2572.942X/2020/3.1269 - DOI

Substances

Supplementary concepts